Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

The denosumab biosimilars Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) are now available in the US.

Shares started a tad lower Wednesday on U.S. President Donald Trump's renewed tariff threats on copper and pharmaceuticals.

The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...

South Korean biopharmaceutical firm Celltrion said Tuesday that it had released its denosumab biosimilars, Stoboclo and ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

SEOUL, July 4 (Yonhap) -- Celltrion Holdings, the holding company of Celltrion Group, a leading South Korean pharmaceutical conglomerate, said Friday it will purchase 500 billion won (US$366 million) ...

Biotechnology corporation Celltrion has expressed its intention to appeal the judgment regarding the 'COVID-19 diagnostic kit lawsuit' against domestic in vitro diagnostic corporation Humasis. On the ...